Answer
It is licensed for selected adults with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after at least two previous tyrosine kinase inhibitors, provided there is no known T315I mutation.
Sources for this answer
- Scemblix 20 mg and 40 mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.